Who are Primary Medical Treatment Pathway's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): REGORAFENIB, PONATINIB HYDROCHLORIDE, Inlyta, PAZOPANIB, PAZOPANIB HYDROCHLORIDE, Sutent.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/primary-medical-treatment-pathway.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Primary Medical Treatment Pathway — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Primary Medical Treatment Pathway (Primary Medical Treatment Pathway) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: anti-VEGF agent. Area: Ophthalmology.

marketed anti-VEGF agent VEGF Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Primary Medical Treatment Pathway (Primary Medical Treatment Pathway) — Moorfields Eye Hospital NHS Foundation Trust. This drug works by inhibiting the action of vascular endothelial growth factor (VEGF) to reduce angiogenesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Primary Medical Treatment Pathway TARGET	Primary Medical Treatment Pathway	Moorfields Eye Hospital NHS Foundation Trust	marketed	anti-VEGF agent	VEGF
REGORAFENIB	REGORAFENIB		marketed		RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAF V600E, SAPK2, PTK5, Abl, CSF1R	2012-01-01
PONATINIB HYDROCHLORIDE	PONATINIB HYDROCHLORIDE		marketed		ABL, T315I mutant ABL, VEGFR, PDGFR, FGFR, EPH receptors, SRC family, KIT, RET, TIE2, FLT3	2012-01-01
Inlyta	Axitinib	Pfizer	marketed	Receptor tyrosine kinase inhibitor	Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3	2012-01-01
PAZOPANIB	PAZOPANIB		marketed	Kinase Inhibitor [EPC]	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-ɑ, PDGFR-β, FGFR-1, FGFR-3, Kit, Itk, Lck, c-Fms	2009-01-01
PAZOPANIB HYDROCHLORIDE	PAZOPANIB HYDROCHLORIDE		marketed		VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, FGFR-1, FGFR-3, Kit, Itk, Lck, c-Fms	2009-01-01
Sutent	Sunitinib Malate	Pfizer	marketed	Small molecule kinase inhibitor	Receptor tyrosine kinases (RTKs): PDGFRα, PDGFRβ, VEGFR1, VEGFR2, VEGFR3, KIT, FLT3, CSF-1R, RET	2006-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (anti-VEGF agent class)

Hawaii Pacific Health · 1 drug in this class
Jaeb Center for Health Research · 1 drug in this class
Moorfields Eye Hospital NHS Foundation Trust · 1 drug in this class
Novartis · 1 drug in this class
ONL Therapeutics · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Primary Medical Treatment Pathway — Competitive Intelligence Brief. https://druglandscape.com/ci/primary-medical-treatment-pathway. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab